You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
瑋俊生物科技(00660.HK)有意投資新冠狀病毒疫苗項目
格隆匯 07-09 08:16

格隆匯 7 月 9日丨瑋俊生物科技(00660.HK)發佈公告,2020年7月8日,公司子公司俊興業有限公司(作為意向投資方)與深圳市倚鋒投資管理企業(有限合夥)訂立不具法律約束力的諒解備忘錄,據此,意向投資方有意投資三個項目關於三個新冠狀病毒疫苗。

根據披露,其中一項新型冠狀病毒mRNA疫苗(“ARCoV”)由艾博生物科技有限公司聯合軍事科學院軍事醫學研究所,雲南沃森生物技術股份有限公司共同開發的疫苗。mRNA疫苗(“ARCoV”)於2020年6月19日通過國家藥品監督管理局臨牀試驗批准,並於近日在樹蘭醫院啟動I期臨牀試驗,這是國內首個獲批開展臨牀試驗的mRNA疫苗。

另外兩種新型冠狀病毒疫苗分別採用CHO細胞表達的S蛋白RBD區域,通過純化後使用,及改進了DNA疫苗的寡核苷酸同時採用電轉的方式進行免疫,提升疫苗遞送效率。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account